Literature DB >> 15823609

Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains.

Li Li1, Alan D T Barrett, David W C Beasley.   

Abstract

Neutralization of flaviviruses by antibody is primarily mediated via epitopes in the viral envelope (E) protein. Comparative studies using neutralizing monoclonal antibodies revealed differential expression of epitopes within the E protein domain III of ten naturally occurring West Nile virus strains representing major subtypes of genetic lineages 1 and 2. Residues that defined these subtype-specific determinants were identified by mutational studies and found to be surface exposed in the domain III structure. Mutations of residue 332 had the most significant effects on variation of domain III neutralizing epitopes among strains.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15823609     DOI： 10.1016/j.virol.2005.02.011

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  28 in total

1.  Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes.

Authors:  Ryuta Kanai; Kalipada Kar; Karen Anthony; L Hannah Gould; Michel Ledizet; Erol Fikrig; Wayne A Marasco; Raymond A Koski; Yorgo Modis
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Authors:  Orly Gershoni-Yahalom; Shimon Landes; Smadar Kleiman-Shoval; David Ben-Nathan; Michal Kam; Bat-El Lachmi; Yevgeny Khinich; Michael Simanov; Itzhak Samina; Anat Eitan; Irun R Cohen; Bracha Rager-Zisman; Angel Porgador
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 3.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

Authors:  Alexander J McAuley; Maricela Torres; Jessica A Plante; Claire Y-H Huang; Dennis A Bente; David W C Beasley
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 5.  Closing the door on flaviviruses: entry as a target for antiviral drug design.

Authors:  Rushika Perera; Mansoora Khaliq; Richard J Kuhn
Journal:  Antiviral Res       Date:  2008-06-11       Impact factor: 5.970

6.  Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.

Authors:  Serafeim C Chaintoutis; Nikolaos Diakakis; Maria Papanastassopoulou; Georgios Banos; Chrysostomos I Dovas
Journal:  Clin Vaccine Immunol       Date:  2015-07-15

7.  Identification of novel small-molecule inhibitors of West Nile virus infection.

Authors:  Amine O Noueiry; Paul D Olivo; Urszula Slomczynska; Yi Zhou; Ben Buscher; Brian Geiss; Michael Engle; Robert M Roth; Kyung Min Chung; Melanie Samuel; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Natural strain variation and antibody neutralization of dengue serotype 3 viruses.

Authors:  Wahala M P B Wahala; Eric F Donaldson; Ruklanthi de Alwis; Mary Ann Accavitti-Loper; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

10.  Transcellular transport of West Nile virus-like particles across human endothelial cells depends on residues 156 and 159 of envelope protein.

Authors:  Rie Hasebe; Tadaki Suzuki; Yoshinori Makino; Manabu Igarashi; Satoko Yamanouchi; Akihiko Maeda; Motohiro Horiuchi; Hirofumi Sawa; Takashi Kimura
Journal:  BMC Microbiol       Date:  2010-06-08       Impact factor: 3.605
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.